• Octapharma launches phase 3 superiority study for PANS pharmaceutical-business-review
    September 08, 2020
    Octapharma has launched a phase 3, multicenter superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome.
PharmaSources Customer Service